Keros Therapeutics (KROS) announced the U.S. Food and Drug Administration granted Orphan Drug designation for KER-065 for the treatment of Duchenne muscular dystrophy.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KROS:
- Keros Therapeutics’ treatment of Duchenne MD granted FDA orphan designation
- Keros Therapeutics Reports Strong Revenue Growth
- Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics
- Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks
- Keros Therapeutics: Hold Rating Amid Strategic Focus on KER-065 and Pipeline Adjustments